What will it take to bring a treatment for COVID-19 to market? What have we learned from efforts to ensure supply chain stability at the height of the coronavirus pandemic? Leaders from AmerisourceBergen's Strategic Global Sourcing team share their perspective on how we'll make sure the right pieces are in place as manufacturers seek to commercialize new therapies.

When the COVID-19 pandemic began to sweep across the U.S. this year, early fears of shortages of critical pharmaceutical supplies and life-saving drugs were quickly abated by a responsive and resilient supply chain.

A recent wave of healthcare policy changes has created new challenges and opportunities for manufacturers. As a manufacturer navigating these tumultuous waters, you can lean on your distributor to rethink and rechart your course through the ever-evolving healthcare landscape.

The only thing certain about 2020 has been uncertainty. Yet, despite the uncertainty, the arrival of COVID-19 galvanized the relationship between policymakers and drug manufacturers and distributors as all sides worked together to tackle shortage risks caused by massive demand surges across the health care supply chain. They also started looking toward the future.